JP6538044B2 - 化学療法感受性および化学毒性を判定する方法 - Google Patents

化学療法感受性および化学毒性を判定する方法 Download PDF

Info

Publication number
JP6538044B2
JP6538044B2 JP2016527380A JP2016527380A JP6538044B2 JP 6538044 B2 JP6538044 B2 JP 6538044B2 JP 2016527380 A JP2016527380 A JP 2016527380A JP 2016527380 A JP2016527380 A JP 2016527380A JP 6538044 B2 JP6538044 B2 JP 6538044B2
Authority
JP
Japan
Prior art keywords
cancer
treatment
cells
patient
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016527380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538539A5 (https=
JP2016538539A (ja
Inventor
ウィリアム イー． ピアーシル，
ウィリアム イー． ピアーシル，
マイケル エイチ． カーダン，
マイケル エイチ． カーダン，
Original Assignee
ユートロピクス ファーマシューティカルズ， インコーポレイテッド
ユートロピクス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユートロピクス ファーマシューティカルズ， インコーポレイテッド, ユートロピクス ファーマシューティカルズ， インコーポレイテッド filed Critical ユートロピクス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2016538539A publication Critical patent/JP2016538539A/ja
Publication of JP2016538539A5 publication Critical patent/JP2016538539A5/ja
Application granted granted Critical
Publication of JP6538044B2 publication Critical patent/JP6538044B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016527380A 2013-10-30 2014-10-30 化学療法感受性および化学毒性を判定する方法 Expired - Fee Related JP6538044B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361897547P 2013-10-30 2013-10-30
US61/897,547 2013-10-30
PCT/US2014/063121 WO2015066305A1 (en) 2013-10-30 2014-10-30 Methods for determining chemosensitivity and chemotoxicity

Publications (3)

Publication Number Publication Date
JP2016538539A JP2016538539A (ja) 2016-12-08
JP2016538539A5 JP2016538539A5 (https=) 2017-12-14
JP6538044B2 true JP6538044B2 (ja) 2019-07-03

Family

ID=53005110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016527380A Expired - Fee Related JP6538044B2 (ja) 2013-10-30 2014-10-30 化学療法感受性および化学毒性を判定する方法

Country Status (5)

Country Link
US (2) US10640803B2 (https=)
EP (1) EP3063302B1 (https=)
JP (1) JP6538044B2 (https=)
AU (1) AU2014342269B2 (https=)
WO (1) WO2015066305A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102062416B1 (ko) * 2012-05-10 2020-01-03 유트로픽스 파마슈티컬스, 인크. 실용 가능한 암 진단 대체 법
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
US9901574B2 (en) * 2015-04-20 2018-02-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
KR20190099260A (ko) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US20210379042A1 (en) * 2018-10-12 2021-12-09 Sumitomo Dainippon Pharma Oncology, Inc. Methods for monitoring tumor lysis syndrome
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP4100955A4 (en) * 2020-02-06 2024-02-28 Oncohost Ltd MACHINE LEARNING PREDICTION OF THERAPEUTIC RESPONSE

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
GB9422836D0 (en) 1994-11-11 1995-01-04 Wainscoat James Monitoring malignant disease
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
WO1998009643A1 (en) 1996-09-09 1998-03-12 Washington University Modulation of apoptosis by serine phosphorylation of blc-xl/blc-2 associated cell death regulator
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
WO1999014321A1 (en) 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
AU9402898A (en) 1997-09-26 1999-04-23 Washington University Cell death agonists
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
AU762756B2 (en) 1998-05-18 2003-07-03 Apoptosis Technology, Inc. Compounds, screening methods, and uses involving anti-apoptotic genes and gene products
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
AU5233799A (en) 1998-08-19 2000-03-14 Washington University Modulation of apoptosis with bid
WO2002005835A2 (en) 2000-07-17 2002-01-24 Washington University Modulation of apoptosis
US7198895B2 (en) * 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
MXPA03005930A (es) 2000-12-28 2003-09-10 Thomson Licensing Sa Presentacion en pantalla como ayuda de diagnostico.
US20020177692A1 (en) 2001-04-16 2002-11-28 Myriad Genetics, Incorporated BCL-XL-interacting protein and use thereof
US7235702B2 (en) 2001-01-16 2007-06-26 Governors Of The University Of Alberta Process for production of alcohols
US20030073661A1 (en) 2001-09-24 2003-04-17 Shigemi Matsuyama Method of modulating or examining Ku70 levels in cells
AU2002364364A1 (en) 2001-12-31 2003-07-24 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
RU2345137C2 (ru) 2002-12-26 2009-01-27 Закрытое акционерное общество "ЕВРОГЕН" Флуоресцирующие белки из веслоногих ракообразных и способы их применения
WO2004066958A2 (en) 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
US7755765B2 (en) 2003-03-17 2010-07-13 Massachusetts Institute Of Technology Method and apparatus for inertial sensing via measurement of trapped orbit dynamics
CA2521077A1 (en) 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers
FR2855650B1 (fr) 2003-05-30 2006-03-03 Soitec Silicon On Insulator Substrats pour systemes contraints et procede de croissance cristalline sur un tel substrat
CN1302004C (zh) 2003-08-22 2007-02-28 浙江海正药业股份有限公司 一种阿糖胞苷的制备方法
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
EP1997828B1 (en) 2003-11-05 2017-10-04 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides from BCL-2 and uses thereof
GB0326964D0 (en) 2003-11-19 2003-12-24 Glaxo Group Ltd Chemical compounds
WO2005079434A2 (en) 2004-02-17 2005-09-01 The University Of North Carolina At Chapel Hill Modulation of epidermal growth factor heterodimer activity
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
WO2008021484A2 (en) 2006-08-16 2008-02-21 Eutropics Pharmaceuticals Assay system to identify therapeutic agents
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR101143246B1 (ko) 2007-06-29 2012-05-18 화이자 인코포레이티드 벤즈이미다졸 유도체
US20090030005A1 (en) * 2007-07-19 2009-01-29 Amgen Inc. Combinations for the treatment of cancer
EP2649997B1 (en) 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
US8168755B2 (en) 2008-05-07 2012-05-01 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of Bcl-2 family and uses thereof
US20100015058A1 (en) 2008-06-25 2010-01-21 Stanford University Radiolabeled bbn-rgd heterodimers for cancer targeting
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
MX2011008488A (es) 2009-02-11 2011-10-24 Abbott Lab Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2.
US20120022057A1 (en) 2009-03-18 2012-01-26 Schering Corporation Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
JP5718319B2 (ja) 2009-05-14 2015-05-13 ネステク ソシエテ アノニム Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
AR077892A1 (es) 2009-08-20 2011-09-28 Vifor Int Ag Quinolinas antagonistas de la hepcidina
AU2011204368B2 (en) 2010-01-06 2014-11-27 Joseph P. Errico Methods and compositions of targeted drug development
WO2011088137A2 (en) * 2010-01-12 2011-07-21 H. Lee Moffitt Cancer Center & Research Institute Bad pathway gene signature
AU2011210567B2 (en) 2010-01-29 2015-04-16 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of MCL-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders
WO2011127333A2 (en) 2010-04-09 2011-10-13 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
EP2596366A4 (en) 2010-07-21 2014-04-16 Joseph P Errico COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS
US8716295B2 (en) 2010-10-27 2014-05-06 Yves Pommier Fluoroquinolone derivatives or sulfonamide moiety-containing compounds as inhibitors of tyrosyl-dnaphosphodiesterase (TDP1)
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9051305B2 (en) 2011-03-08 2015-06-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9012215B2 (en) 2011-09-22 2015-04-21 The Johns Hopkins University Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
WO2013138702A2 (en) 2012-03-15 2013-09-19 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
KR102062416B1 (ko) 2012-05-10 2020-01-03 유트로픽스 파마슈티컬스, 인크. 실용 가능한 암 진단 대체 법
WO2016196358A1 (en) * 2015-05-29 2016-12-08 Epicentre Technologies Corporation Methods of analyzing nucleic acids

Also Published As

Publication number Publication date
WO2015066305A1 (en) 2015-05-07
US20160273020A1 (en) 2016-09-22
US11519015B2 (en) 2022-12-06
AU2014342269B2 (en) 2020-02-27
EP3063302A4 (en) 2017-04-05
AU2014342269A1 (en) 2016-05-05
US20200283819A1 (en) 2020-09-10
JP2016538539A (ja) 2016-12-08
US10640803B2 (en) 2020-05-05
EP3063302A1 (en) 2016-09-07
EP3063302B1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
JP6538044B2 (ja) 化学療法感受性および化学毒性を判定する方法
US20180246106A1 (en) Surrogate functional diagnostics test for cancer
US10624880B2 (en) Predicting response to alvocidib by mitochondrial profiling
US20190257816A1 (en) Differential bh3 mitochondrial profiling
US20180100859A1 (en) Surrogate functional biomarker for solid tumor cancer
US20200392585A1 (en) Context dependent diagnostics test for guiding cancer treatment
HK1228469A1 (en) Methods for determining chemosensitivity and chemotoxicity
HK1228469B (en) Methods for determining chemosensitivity and chemotoxicity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190605

R150 Certificate of patent or registration of utility model

Ref document number: 6538044

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees